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Abstract
Introduction. Pyocephalus always presents serious complications in the treatment of brain abscesses, and is associated with 
high rates of mortality and morbidity. This study aimed to comprehensively evaluate this understandably feared complication 
from a purely medical perspective by using an evidence-based approach and drawing comparisons from the available literature, 
which mostly comprises case reports.
Methods. This was a prospective monocentric study of all patients treated for brain abscesses at the Neurosurgery Clinic of the 
University Hospital Ostrava between 2012 and 2017. The cohort was divided into two groups for statistical comparison; one 
group comprised those in which pyocephalus occurred before or during treatment, while the other group comprised patients 
without this complication. Particular consideration was given to the effect of pyocephalus on morbidity and mortality rates and 
C-reactive protein levels, as well as to the identification of risk factors, and to its possible therapeutic influence. Patients were 
followed up for six months.
Results. A total of 43 patients were treated for a brain abscess. An unequivocal diagnosis of pyocephalus was established via 
CT and MRI brain scans in five cases (11.6%). In the cohort as a whole, mortality and morbidity rates were 23.3% and 48.8% 
respectively. Among patients with pyocephalus the incidence of mortality and morbidity was 40% and 66.6% respectively. The 
presence of pyocephalus is not a significant predictor of either morbidity (p 0.575) or mortality (p 0.664). In patients with py-
ocephalus, we determined elevated CRP levels on the day of surgery (p 0.038). The occurrence of epileptic seizures in the acute 
phase of the disease is associated with a poor outcome (p 0.039).
Conclusions. Pyocephalus will continue to be a serious complication in the treatment of brain abscesses, although we were 
unable to determine its utility as a prognostic factor. Patients with this complication have elevated CRP levels on the day of 
operation.
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Introduction
A brain abscess is a serious inflammatory illness with an un-
certain prognosis. Treatment outcome is influenced not only by 
a range of underlying factors including age at onset, associated 
diseases and immune system status, but also by the localisation 
of the abscess. For example, an abscess close to the ventricle 
can rupture, leading to the spontaneous effusion of pus into the 
ventricular system, with the resultant ventriculitis manifesting 
as sepsis or even septic shock. A diagnosis of pyocephalus can 
be made initially or as it arises over the course of treatment 
and is frequently associated with sudden clinical deterioration. 
The risk of this complication is considered to be higher with 
the presence of multilocular or deep-seated abscesses close to 
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the ventricles [1], and can occur in as many as 35% of cases 
[1, 2]. Mortality rates are high, ranging from 40–85% [1–4]. 
In addition to the standard therapies presently carried out, the 
treatment of pyocephalus can involve ventricular drainage to 
discharge purulent CSF accompanied by the intraventricular 
administration of antibiotics, with glycopeptide vancomycin 
being the one most commonly recommended in case studies [5, 
6]. Even so, an established therapeutic strategy for this special 
subgroup of patients remains controversial, being led as it is 
by empirical experience of the workplace and each individual 
patient’s clinical development. 
Methods
Study design
This prospective monocentric study was carried out at 
the Neurosurgery Department of the University Hospital 
Ostrava between 2012 and 2017, and comprised all patients 
who received treatment for a brain abscess during this period. 
The diagnosis was confirmed upon admission by imaging 
studies. Initial CT scans were performed on all patients, 
supplemented by MRI conducted according to the standard 
protocol consisting of T1- and T2-weighted images, FLAIR, 
DWI with application of contrast material as standard and also 
spectroscopy sequencing. For a positive diagnosis of abscess 
it is always necessary to observe restriction on diffusion-wei-
ghted images while taking into account clinical condition and 
laboratory findings.. Patients with pyocephalus were assigned 
to one study group, while a second group comprised patients 
without this complication. Therapeutic algorithms were 
identical in both groups: initial broad-spectrum empirical 
antibiotic treatment was modified according to culture fin-
dings, preliminary laboratory findings and the establishment 
of inflammation markers (CRP) while always investigating 
the origin of the abscess and carrying out surgical treatment. 
All patients underwent surgery within 24 hours of diagnosis. 
The type of operation was chosen according to the localisa-
tion and the patient’s clinical condition. Guided aspiration 
was carried out on deep-seated lesions in affected areas and 
residua surgically excised, with samples of the purulent fluid 
taken away for culture. We carried out external ventricular 
drainage (EVD) on patients with pyocephalus (excepting that 
this procedure was not indicated for one patient who was in 
good clinical condition). Patients were followed up for six 
months. Outcome was determined on the basis of the modi-
fied Rankin Scale (mRS) (Tab. 1). This study was approved 
by the local Ethics Committee. 
Statistical evaluation of the study group
Statistical comparison was carried out using the IBM SPSS 
(version 25) statistics program. We focused on morbidity 
and mortality rates, risk factor identification and potential 




A total of 43 patients (24 male, 19 female) were treated, 
including four children. The average age was 45 years for men 
and 55 for women. The youngest patient was a 5 year-old boy, 
the oldest an 86 year-old woman. Pyocephalus was clearly 
determined by CT and MRI scans in five patients (11.6% of 
cases). Overall mortality in our study reached 23.3%, while 
the morbidity rate was 48.8% (mRS 1–5). Among patients 
with simple abscess, the mortality rate was 21% and morbidity 
36.8%. The causes of death were four cases of accented perifo-
cal oedema accompanied by rapid craniocaudal deterioration, 
one case of extensive bleeding along the puncture trajectory, 
two cases of progressive sepsis and one case of cardiopulmo-
nary failure. Among patients with pyocephalus, mortality was 
40% and morbidity 66.6%. In our study, pyocephalus was not 
a statistically significant predictor of either morbidity (p 0.575, 
exact test) or mortality (p 0.664, exact test). Two patients with 
pyocephalus died within 14 days with symptoms of persistent 
sepsis and progressive multiple organ failure. One patient 
successfully underwent CPR following spontaneous ventri-
cular fibrillation on the eighth day of treatment. Regarding 
the morbidity of cured patients, there were two instances of 
residual hemiparesis and psycho-organicity (mRS 3), and 
one case without any long-term ill effects (mRS 0). Patient 
characteristics, along with surgical procedures and culture 
findings, can be found in Table 2.
Seizures
Five patients (11.6%) had multiloculated lesions, of which 
one patient had pyocephalus. The remaining 88.4% had uni-
loculated lesions. The total number of lesions was 50. Most 
were located at the frontal lobe (38%, epilepsy risk p 0.309), 
followed by the temporal lobe (22%, p 0.778), occipital lobe 
(14%, p 0.904) and parietal lobe (12%, p 0.524). 4/50 were at 
deep-seated structures such as the basal ganglion and brain-
stem (8%, p 0.267), with 3/50 at the cerebellum (6%, p 0.224). 
The effect of abscess location on the incidence of epileptic 
seizure could not be determined.
Table 1. Outcome after six months
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The frequency of epileptic seizures, both generalised and 
partial, was noted over the six-month monitoring period. 
32.5% of patients (14/43) were symptomatic in the acute 
phase of the illness. Ten patients exhibited partial seizures, 
with generalised seizures in the remaining four, while 11 cases 
exhibited one-off incidences in the initial or early stage of 
the illness up to 72 hours post diagnosis, with no recurrence 
following treatment. In one case it was necessary to place 
the patient in a barbiturate-induced coma after suffering 
status epilepticus. This patient died shortly thereafter from 
cardiorespiratory complications. The period prescribed for 
anti-epileptics did not exceed that of antibiotics (a maximum 
of six weeks). Just one patient required long-term medication 
for chronic epilepsy after the conclusion of treatment. The 
occurrence of epileptic seizures in the acute stage of the illness 
is an indicator of a poor long-term prognosis (p 0.039, χ2 test), 
as are persistent mRS values in the range 2–5 with various 
presentations of hemiparesis, and impaired psychological and 
language function being most typically described. It was not 
found to affect mortality rates (p 1.000, exact test).
Surgical approach
Guided aspiration of lesions was carried out in 51.2% 
(22/43) of cases. There were six reoperations among this 
subgroup: three punctures were carried out repeatedly on one 
patient who had pyocephalus; one operation was extended to 
include excision after adverse MRI findings postoperatively; 
one revision of puncture trajectory was performed due to 
haematoma, and in another case it was necessary to perform 
hemicraniectomy for accentuated perifocal oedema. Excision 
was primarily performed in 48.8% (21/43) of cases. In three 
cases, reoperation was performed 14 days after the primary 
operation following ambiguous findings on postoperative 
MRI studies (i.e. partial persistence of diffusion restriction 
and no indication of regression in lesion size). In another 
case, acute revision was necessary due to haematoma in the 
surgical field with the onset of herniation.
Laboratory findings and origin of infection
Average initial CRP levels were 26 mg/l in patients wit-
hout complications and 82.4 mg/l in those with pyocephalus. 
Physiological CRP was present in 19 of our study patients 
(44.1%) on the day of operation (< 8 mg/l). We determined 
statistically higher CRP levels in patients with pyocephalus 
(p 0.038, median test).
The underlying cause of the abscess could not be estab-
lished in a quarter of patients. The most common source was 
haematogenous spread, followed by infection of the paranasal 
sinus and teeth. The least common cause was middle ear 
infection. We noted abscess progression as a postoperative 
complication in seven patients (Tab. 3). Culture remained 
sterile in 51.1% of samples. No mycotic or tuberculous abs-
cesses were treated during this study. Two cases of extended 
cultivation eventually isolated aerobic Nocardia (Tab. 4). In 
the pyocephalus subgroup, positive culture was found in 80% 
of cases, with one patient in a good clinical state and culture-
-negative. This was due to intraventricular rupture occurring 
some time after antibiotic therapy with the patient’s condition 
not indicating drainage. The remaining patients had initial 
pyocephalus. In these we carried out aspiration to evacuate 
pus from the affected lateral ventricle. In two patients this was 
performed as part of the primary operation prior to abscess 













44 / M sopor, neck 
stiffness
middle ear right temporal 
lobe
excision yes Prevotella sp.,  
Bacteroides sp. 
alcoholism mRS 6
53 / M fever unknown left basal ganglia aspiration yes Streptococcus 
intermedius
hypertension mRS 3
77 / F somnolence, 
hemiparesis
unknown right parietal lobe excision yes Streptococcus 
intermedius
hypertension mRS 6


















left frontal lobe aspiration no negative none mRS 0
Table 3. Origin of infection
Origin of infection n = 43 (100%)
unknown 11 (25.6%)
paranasal sinusitis 6 (14%)
otitis media 4 (9%)
haematogenous 9 (21%)
complication of therapy (iatrogenic) 7 (16.3%)
dental 6 (14%)
165www.journals.viamedica.pl/neurologia_neurochirurgia_polska
Zdeněk Večeřa et al., Brain abscess and pyocephalus: our experience with treatment
Table 4. Culture findings
Culture findings n = 43 (100%)
aerobic origin 7 (16.3%)
anaerobic origin 6 (14%)
mixed cultures 8 (18.6%)
atypical 0
sterile cases 22 (51.1%)
excision. In the remaining two this was performed some 
time later on the basis of ventricular progression observed 
by imaging studies. In one case we performed drainage of 
both ventricles for a bilateral foramen of Monro obstruction 
(Fig. 1), although this patient died soon after. The remaining 
patient underwent EVD two days postoperatively for the pro-
gression of unilateral hydrocephalus affecting the left lateral 
ventricle (Fig. 2). In this case, the drain was left in place for 
four weeks. Repeated attempts to remove were unsuccessful 
due to the isolated nature of the left lateral ventricle – the 
situation was resolved by performing guided endoscopic 
septostomy from the right-hand side. In another surviving 
patient the drain was left in place for 14 days, after which 
it was discontinued due to malplacement causing patient 
discomfort. Regular MRI follow-up found the ventricular 
system to be stable. VP shunts were not required on any 
patients in the study. We did not administer antibiotics 
intraventricularly — all patients were treated intravenously 
as is standard, initially with the recommended combination 
antibiotic therapy (2–3 g cefotaxime with 0.5 g metronida-
zole every eight hours; vancomycin separately in the case of 
postoperative complications) adjusted as necessary according 
to culture.
The study included seven immunocompromised patients 
(16.3%), none of whom had pyocephalus. In one patient 
this was due to kidney transplantation, and two others were 
undergoing radio- and chemotherapy. The remaining four 
patients were chronically immune-suppressed due to rheu-
matoid arthritis. Immunosuppression did not affect either 
morbidity (p 0.240, exact test) or mortality (p 1.000, exact 
test). The most commonly-occurring underlying diseases 
Figure 1. Bilateral external drainage in a patient with isolated lateral ventricles
Figure 2. CT image of drained lateral ventricle in a case of uni-
lateral hydrocephalus. Complication was resolved by performing 
guided endoscopic septostomy
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were hypertension in 18 patients (36%) and diabetes in six 
patients (12%). Neither hypertension (p 0.322) nor diabetes 
(p 0.526) had any effect on mortality rates.
Discussion
Outcome and factors related to outcome
Even with improved imaging techniques and a variety of 
specific neurosurgical approaches at our disposal, brain abs-
cesses remain a diagnosis with a highly uncertain prognosis 
that is dependent on their localisation. Overall condition, 
age and accompanying illnesses all play an important role in 
treatment outcome. 
Our findings concerning mortality and morbidity rates 
are consistent with current experience. Statistically, the 
presence of pyocephalus and immuno-suppression did 
not influence the outcome, nor could we determine that 
immunosuppression has an influence on the incidence of 
pyocephalus. The most common underlying conditions were 
hypertension and diabetes (36% and 12% respectively). We 
could not determine if these factors affected the outcome. 
Xiao et al studied 178 patients treated between 1986 and 
2002 and described only four patients with pyocephalus, 
two of whom died during the study. Neither pyocephalus, 
diabetes nor cirrhosis were found to effect the outcome. 
Only initial GCS, immunodeficiency and the presence of 
underlying disease were found to have a significant influence 
on the outcome [7]. In the discussion of the range of epide-
miological factors involved, we can refer to a retrospective 
study of brain abscess cases from 2002–2017 conducted by 
Amornpojnimman et al in Thailand.The authors considered 
immunosuppression to be the most significant risk factor in 
the formation of abscesses. Confusion as a symptom of septic 
encephalopathy is associated with a poor outcome (GOS 1). 
In this study, there was a high proportion of immunocompro-
mised patients (42%), although this figure included patients 
with diabetes (16%). This study also included 10 cases of 
HIV (12.3%), as opposed to none in our study. There was 
only one case of spontaneous pyocephalus (1.2%). The most 
frequently-occurring complication mentioned was hydro-
cephalus, in 17.3% of patients, but the study lacked a further 
appraisal of the treatment or information as to whether EVD 
was necessary [8]. Kao et al reported that short duration 
of symptoms, diabetes and cirrhosis were associated with 
poor outcomes in 53 patients [9]. Another study by the Thai 
authors concluded that spontaneous intraventricular rupture 
and fungal abscesses were predictors of a poor outcome [10]. 
A series of earlier case studies considered pyocephalus as 
a malign symptom associated with an adverse outcome [2, 3, 
6]. In a study of 179 patients treated between 1986 and 2005, 
Lee et al identified the risk factors predictive of ventricular 
rupture to be size and multiloculation of abscesses, and their 
proximity to the ventricular system. This study included 
a high overall incidence of intraventricular rupture (34.6%). 
25.2% of patients were initially diagnosed and 9.4% were 
diagnosed over the course of treatment. Mortality among this 
subgroup of patients was 26.7% at three months. The surgical 
therapy described for this cohort consisted of stereotactic 
aspiration or excision; this study does not mention if EVD 
was eventually necessary, or if there were complications in 
terms of hydrocephalus [1].
Treatment modalities of pyocephalus
Ventricular drainage may be performed on the basis 
of the patient’s clinical state, imaging findings and the 
response to routine antibiotic therapy. Drainage was not 
indicated in one patient in good clinical condition in 
which pyocephalus occurred three weeks after treatment 
for purulent meningitis, accompanied by severe headaches 
and fever and the recurrence of meningeal irritation. In the 
remaining patients, drainage was required for a possible 
unilateral foramen of Monro obstruction causing hydro-
cephalus. Black et al described a similar experience in the 
treatment of a ruptured thalamic abscess, although with 
complications arising five weeks after the commencement 
of treatment [11]. Brewer et al recommended drainage as 
a routine therapy in a paper published in 1975 [12]. The 
intraventricular administration of vancomycin has been 
presented as a successful treatment for pyocephalus in 
a number of previous case studies [6, 13, 14] although this 
approach has been unsuccessful in other cases involving 
gentamicin [15]. Two patients died early on in our study 
from ongoing sepsis and multiple organ failure. The cause 
of death was not hydrocephalus and even prompt and 
aggressive antibiotic therapy was ineffective. 
While we believe this approach remains the most appro-
priate in such cases, it does mean that improving patient 
outcome will, for the time being, continue to be proble-
matic. The appropriate surgical technique depends on the 
localisation and the character of the findings. All of these 
patients were culture-positive, therefore we can assume 
active inflammation and the possible inefficacy of antibiotic 
therapy. Furthermore, the permeation of antibiotics into 
a developed, encapsulated abscess remains debatable and 
the therapeutic effect impossible to determine directly. Only 
cefotaxime, ceftazidime, imipenen and metronidazole have 
been proven to penetrate the abscess capsule in vivo [16–19]. 
A rare minimally-invasive approach is presented by Nishizaki 
et al, where the patient successfully underwent evacuation 
of the intraventricular abscess using a neuro-endoscope. 
The material was collected for bacterial culture, resulting in 
gentamicin sulphate being administered twice daily for nine 
days in combination with intravenous cefotaxime sodium for 
14 days. The patient made a full recovery [20]. 
Vancomycin is the subject of most research in the intra-
ventricular administration of antibiotics. It is considered to 
be safe in a wide range of doses, from 0.075–50 mg per day. 
5–20 mg is the most frequently recommended daily dose to 
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achieve a sterile fluid. Only a few instances of side effects 
have been noted, such as leukocytosis [21] and severe heada-
ches when administered via an Ommaya reservoir [22]. The 
pharmacokinetics of vancomycin in the ventricular system 
are unclear, relying as they do on several possible population 
models, with a range of complicating factors including severe 
infection, obstruction of CSF flow in hydrocephalus or the 
presence of drainage [5].
Laboratory findings
Elevation of inflammation markers in abscesses tends to 
be unspecific and does not reflect the severity of the illness. 
Infections in isolated compartments such as the CNS as 
protected by the blood-brain barrier induce only minimal 
or slight system changes that can be detected in serum, as 
reflected in our findings — physiological CRP levels were 
found in 44.1% of our study patients. Helweg-Lareson et al 
conducted a retrospective study of 102 patients and found that 
26% of the cohort had low CRP (< 20 mg/l) and that 49% were 
without leukocytosis. CRP levels were not found to influence 
outcome [23]. Similarly, Ko et al, in a retrospective study, 
found initial CRP values to be normal in 39% of the study 
group [24]. We determined statistically higher CRP among 
patients with pyocephalus on the day of surgery. However, 
the current lack of similar published studies means it is not 
possible to corroborate these findings. 
Severe ventriculitis resulting in sepsis, being the system’s 
reaction to insult, elevates acute inflammatory parameters in 
serum, as consistent with our findings. CRP cannot therefore 
be taken to be a reliable indicator of a successfully treated 
infection, and should only be used to supplement imaging 
and clinical findings in the decision to end antibiotic therapy.
Localisation
Regarding the supratentorial and infratentorial regions, 
brain abscesses occur overwhelmingly more frequently in the 
former. We found abscesses to be most commonly localised in 
the frontal or frontoparietal lobe, as consistent with other studies 
[1, 7, 25]. In a cohort of 51 patients, Cavusoglu et al demon-
strated its typical occurrence in the temporoparietal lobe [26].
Seizures
Epileptic seizures in the acute phase are relatively com-
mon, occurring in 13-50% of patients [1, 7, 9, 27–30]. 30–50% 
of patients are at risk of late seizures or chronic epilepsy 
[27–31]. In a three-year study, Buonaguro et al described 
late seizures in 7/29 children (24%) [32]. In our study, there 
was just one patient who experienced repeated seizures 
requiring combination antiepileptics after six months. The 
remaining initially symptomatic patients were prescribed 
anticonvulsants until the conclusion of antibiotic therapy 
and for a maximum of three months. Abscess localisation in 
the frontoparietal lobe is a possible risk factor [33], although 
this could not be confirmed in our study. 
It is also necessary to consider the role of medication in 
inducing seizures: Martin-Canal et al documented a signi-
ficantly higher incidence of convulsions in patients treated 
with imipenem compared to meropenem, and recommended 
this and carbapenem in such cases. The pharmacokinetic 
and microbial effect is thought to be broadly similar if not 
identical. Additionally, no seizures were noted in a group 
administered only metronidazole and cephalosporins [34]. 
In children, the administration of anticonvulsants should be 
individualised on the basis of EEG monitoring [30]. Most 
authors recommend the prophylactic prescription of medica-
tion for three months [35]. One possible weakness of the study 
is the six-month follow up period, given the potential for the 
late onset or recurrence of seizures, especially in children. At 
least two years of follow up is required to properly evaluate 
this complication.
Conclusion
Although its prognostic value remains uncertain, we do 
know that pyocephalus will continue to be a serious compli-
cation in the treatment of brain abscesses, initially requiring 
prompt and aggressive antibiotic therapy supplemented by 
surgical treatment of lesions. We find EVD to be an appro-
priate procedure for the aspiration of purulent material, and 
useful for both the prevention of acute hydrocephalus and 
the possibility of directly administering antibiotics. We were 
unable to identify any risk factors associated with the deve-
lopment of  this complication. These patients have statistically 
higher CRP on the day of operation. The occurrence of epi-
leptic seizures in the acute phase of brain abscess treatment 
is a poor prognostic factor.
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